1000001	NCCN Guidelines Non-Small Cell Lung Cancer	NCCN Guidelines Non-Small Cell Lung Cancer	Version 3.2022
1000002	CSCO非小细胞肺癌诊疗指南	CSCO非小细胞肺癌诊疗指南	2022
1000003	FDA		
1000004	NMPA		
1000005	NCCN指南指出大多数EGFR 20外显子插入突变为EGFR-TKI耐药突变，但是p.A763_764insFQEA和p. A763_Y764insLQEA除外，p.A763_Y764insFQEA对EGFR-TKI治疗敏感，而p.A763_Y764insLQEA对第一、三代EGFR-TKI治疗敏感。		
1000006	NCCN非小细胞肺癌指南提示，Amivantamab-vmjw可用于治疗铂类化疗后进展的EGFR第20号外显子插入突变的局部晚期或转移性非小细胞肺癌患者。		
1000007	CSCO非小细胞肺癌诊疗指南提示，Amivantamab-vmjw用于EGFR第20号外显子插入突变的IV期NSCLC的后线治疗(III级推荐)。		
1000008	NCCN非小细胞肺癌指南提示，Mobocertinib可用于治疗铂类化疗后进展的EGFR第20号外显子插入突变的局部晚期或转移性非小细胞肺癌患者。		
1000009	CSCO非小细胞肺癌诊疗指南提示，Mobocertinib用于IV期EGFR第20号外显子插入突变的IV期NSCLC的后线治疗(III级推荐)。		
1000010	NCCN非小细胞肺癌指南提示，拉罗替尼可用于NTRK1/2/3基因融合阳性的转移性NSCLC患者的一线治疗。		
1000011	NCCN非小细胞肺癌指南提示，entrectinib可用于NTRK1/2/3基因融合阳性的转移性NSCLC患者。		
1000012	NCCN非小细胞肺癌指南提示，entrectinib可用于NTRK1/2/3基因融合阳性的转移性NSCLC患者的一线治疗。		
1000013	NCCN非小细胞肺癌指南提示，EGFR T790M突变是非小细胞肺癌接受第一代第二代EGFR TKI后的获得性耐药突变。		
1000014	NCCN非小细胞肺癌指南提示，对于接受厄洛替尼、吉非替尼、阿法替尼或达可替尼治疗进展的EGFR T790M阳性的转移性NSCLC患者，推荐使用奥希替尼作为二线和后续治疗。		
1000015	NCCN Guidelines Colon Cancer	NCCN Guidelines Colon Cancer	Version 1.2022
1000016	NCCN Guidelines Breast Cancer	NCCN Guidelines Breast Cancer	Version 3.2022
1000017	NCCN Guidelines Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer	NCCN Guidelines Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer	Version 1.2022
1000018	NCCN Guidelines Bladder Cancer	NCCN Guidelines Bladder Cancer	Version 1.2022
1000019	NCCN Guidelines Hepatobiliary Cancers	NCCN Guidelines Hepatobiliary Cancers	Version 1.2022
1000020	CSCO胆道恶性肿瘤诊疗指南	CSCO胆道恶性肿瘤诊疗指南	2021
1000021	NCCN Guidelines Gastric Cancer	NCCN Guidelines Gastric Cancer	Version 2.2022
1000022	CSCO胃癌诊疗指南	CSCO胃癌诊疗指南	2021
1000023	NCCN Guidelines Thyroid Carcinoma	NCCN Guidelines Thyroid Carcinoma	Version 2.2022
1000024	CSCO分化型甲状腺癌诊疗指南	CSCO分化型甲状腺癌诊疗指南	2021
1000025	NCCN Guidelines Melanoma: Cutaneous	NCCN Guidelines Melanoma: Cutaneous	Version 3.2022
1000026	NCCN Guidelines Gastrointestinal Stromal Tumors (GIST)	NCCN Guidelines Gastrointestinal Stromal Tumors (GIST)	Version 1.2022
1000027	CSCO胃肠道间质瘤诊疗指南	CSCO胃肠道间质瘤诊疗指南	2021
1000028	NCCN Guidelines Pancreatic Adenocarcinoma	NCCN Guidelines Pancreatic Adenocarcinoma	Version 1.2022
1000029	CSCO胰腺癌诊疗指南	CSCO胰腺癌诊疗指南	2021
1000030	NCCN Guidelines Prostate Cancer	NCCN Guidelines Prostate Cancer	Version 4.2022
1000031	CSCO前列腺癌诊疗指南	CSCO前列腺癌诊疗指南	2021
1000032	NCCN Guidelines Esophageal and Esophagogastric Junction Cancers	NCCN Guidelines Esophageal and Esophagogastric Junction Cancers	Version 2.2022
1000033	NCCN Guidelines Central Nervous System Cancers	NCCN Guidelines Central Nervous System Cancers	Version 2.2021
1000034	" Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal."	" Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal."	
1000035	Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 2017;133:1001-1016. Available at:	Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 2017;133:1001-1016. Available at:	
